33 filings
8-K
OLMA
Olema Pharmaceuticals Inc
11 Mar 24
Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
4:05pm
8-K
OLMA
Olema Pharmaceuticals Inc
8 Jan 24
Olema Oncology JP Morgan Conference January 2024
9:07am
8-K
OLMA
Olema Pharmaceuticals Inc
8 Jan 24
Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate
8:18am
8-K
OLMA
Olema Pharmaceuticals Inc
5 Jan 24
Entry into a Material Definitive Agreement
5:26pm
8-K
OLMA
Olema Pharmaceuticals Inc
6 Dec 23
Regulation FD Disclosure
7:48am
8-K
4wqj w3vkpzvrgmjrnum
5 Dec 23
Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies
5:15pm
8-K
2euzzhty
7 Nov 23
Olema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:10pm
8-K
4ml 8e5qva9f
23 Oct 23
Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant
7:45am
8-K/A
9bxioje u3lchbs4apm
18 Oct 23
Olema Oncology Appoints Oncology Biotech Executive Scott Garland to Board of Directors
4:46pm
8-K
5e96wq4bxoy9
17 Oct 23
Olema Oncology Appoints Oncology Biotech Executive Scott Garland to Board of Directors
7:33am
8-K
ijx9ir dbpuy
10 Oct 23
Olema Oncology Announces Expansion of Collaboration
7:17am
8-K
kn8wzcdac079zxbwq
5 Sep 23
Olema Oncology Announces Combined Financing for Up to $180 Million
7:39am
8-K
n3egfi7lgcn amdya1
8 Aug 23
Olema Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:09pm
8-K
0p5f6ikbkkhg rq
21 Jun 23
Submission of Matters to a Vote of Security Holders
4:31pm
8-K
mw4e1pcn fa5i75
11 May 23
Olema Oncology Announces OP-1250 Continues to Demonstrate Attractive Combinability with CDK4/6 Inhibitor Palbociclib in Phase 1b/2 Study
9:24am
8-K
h0w3wxfeq0hec zg3zo
9 May 23
Olema Oncology Reports First Quarter 2023 Financial Results and Provides Corporate Update
4:06pm
8-K
v4bxzwxzahaa vpbhwl
10 Mar 23
Regulation FD Disclosure
4:17pm
8-K
zswzlcehnj 0yp
9 Mar 23
Olema Oncology Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Strategic Update
4:07pm
8-K
3z8ocbj0ewk8b0h0
16 Dec 22
Amendments to Articles of Incorporation or Bylaws
4:05pm
8-K
clkdl5bd
8 Nov 22
Olema Oncology Reports Third Quarter 2022 Financial Results and Provides Corporate Update
4:42pm